Tian J H, Good M F, Hirunpetcharat C, Kumar S, Ling I T, Jackson D, Cooper J, Lukszo J, Coligan J, Ahlers J, Saul A, Berzofsky J A, Holder A A, Miller L H, Kaslow D C
Laboratory of Parasitic Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Parasite Immunol. 1998 Jun;20(6):263-78. doi: 10.1046/j.1365-3024.1998.00138.x.
MSP1(19) is one of the leading malaria vaccine candidates. However, the mechanism of protection is not clear. To determine whether MSP1(19)-specific effector T cells can control parasitaemia, we analysed the specificity of T cells induced following immunization with recombinant forms of P. yoelii MSP1(19) and asked whether they could protect mice. There was no evidence that effector T cells were capable of protecting since: (1) immunization of mice with yMSP1(19), but not defined epitopes, was able to induce protection; and (2) long term MSP1(19)-specific CD4+ T cell lines were incapable of adoptively transferring protection. In contrast, priming mice with the T cell epitopes resulted in a rapid anamnestic antibody response to MSP1(19) after either challenge with MSP1(19) or parasite. Thus, MSP1(19) contains multiple T cell epitopes but such epitopes are the targets of helper T cells for antibody response but not of identified effector T cells capable of controlling parasitaemia.
疟原虫裂殖子表面蛋白1（19）[MSP1(19)]是主要的疟疾疫苗候选物之一。然而，其保护机制尚不清楚。为了确定MSP1(19)特异性效应T细胞是否能够控制疟原虫血症，我们分析了用重组约氏疟原虫MSP1(19)免疫后诱导的T细胞的特异性，并询问它们是否能够保护小鼠。没有证据表明效应T细胞具有保护能力，原因如下：（1）用约氏疟原虫MSP1(19)而非特定表位免疫小鼠能够诱导保护作用；（2）长期的MSP1(19)特异性CD4+ T细胞系无法通过过继转移发挥保护作用。相反，用T细胞表位免疫小鼠后，在用MSP1(19)或疟原虫攻击后，会对MSP1(19)产生快速的回忆性抗体反应。因此，MSP1(19)含有多个T细胞表位，但这些表位是辅助性T细胞引发抗体反应的靶标，而非能够控制疟原虫血症的已确定效应T细胞的靶标。
